Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Triple-blind Treatment

Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality

Myopia-Night Blindness

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Night Myopia — -0.30; -0.32 D

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Spectacle/Glasses (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Applied Sciences Jena
Primary completion
Feb 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Night Myopia
-0.30; -0.32
SECONDARY
Mesopic Visual Acuity Improvement
0.1; 0.1; 0.1
SECONDARY
Subjective Vision Comfort in Dark Light Conditions
60; 73
SECONDARY
Subjective Vision Sharpness in Dark Light Conditions
59; 73
SECONDARY
Subjective Glare Sensitivity in Dark Light Conditions
48; 37
SECONDARY
Subjective Driving Safety in Dark Light Conditions
57; 73

Summary

Reduced quality of vision and glare in twilight or night are frequently mentioned complaints within the optometric examination. A reason for these problems could be a myopic refractive shift in dark light conditions, commonly known as night myopia or twilight myopia. The aim of this study was to investigate whether quality of vision in twilight or night could be improved by a spectacle correction optimized for mesopic light conditions. Moreover, objective refraction in large pupils measured by aberrometry was compared to subjective mesopic refraction.

Eligibility Criteria

Inclusion Criteria

  • Visual Acuity at least 0.8 (5/6)
  • Binocular Vision

Exclusion Criteria

  • refraction more than sph +/- 6 D and cyl 2 D
  • Difference between habitual correction and actual refraction more than 0.5 D
  • Medication with an influence on visual system
  • Disease or eye disease with an effect on the visual system
  • pregnancy or other hormonal variances
  • influence of drugs
  • mental handicap
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02965534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search